In an unprecedented move, a government panel decided Wednesday to cut the official price of cancer drug Opdivo by 50 percent, amid fears that widespread use of the newly approved and super-expensive drug could drain state coffers.
The Central Social Insurance Medical Council, better known as Chuikyo and comprised of medical interest group representatives, decided on the emergency price-cutting measure targeting Opdivo, an anti-cancer drug developed by Ono Pharmaceutical Co.
The drug, which stimulates the body's natural immune system to fight off tumors, was initially approved for use among a small number of patients with advanced melanoma, but was expanded last year to patients with lung cancer, who number in the tens of thousands.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.